StockNews.AI
URGN
StockNews.AI
173 days

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

1. UroGen Pharma will report Q4 and full-year 2024 results on March 10, 2025.

Earnings
+0.27%Current Return
VS
-1.17%S&P 500
$9.3602/27 08:14 AM EDTEvent Start
$9.38502/28 02:58 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements can lead to volatility, but no new developments reported.

How important is it?

Upcoming earnings report may influence investment decisions, albeit without significant new information.

Why Short Term?

Immediate market reaction expected around the earnings announcement date.

Related Companies

URGN
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings confer.

Related News